<?xml version="1.0" ?>
<document id="968d0b07b0b65a15cedfd2357e3ba9649742836e">
  <chunk id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0" text="Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions">
    <entity charOffset="19-51" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e0" ontology_id="DOID_627" text="severe combined immunodeficiency" type="disease"/>
    <entity charOffset="26-51" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e1" ontology_id="DOID_628" text="combined immunodeficiency" type="disease"/>
    <entity charOffset="162-167" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e2" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="162-167" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e3" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e2" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.p0" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e3" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.p1" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e2" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.p2" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.e3" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c0.p3" relation="true"/>
  </chunk>
  <chunk id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1" text="Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an increased risk of graft-versus host-disease (GvHD) with HSCT. Early intervention is a crucial prognostic factor and a HLA-haploidentical parental donor is often available. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells.">
    <entity charOffset="115-147" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e0" ontology_id="DOID_627" text="severe combined immunodeficiency" type="disease"/>
    <entity charOffset="122-147" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e1" ontology_id="DOID_628" text="combined immunodeficiency" type="disease"/>
    <entity charOffset="366-371" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e2" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="366-371" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e3" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <entity charOffset="671-675" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e4" ontology_id="DOID_627" text="SCID" type="disease"/>
    <entity charOffset="805-810" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e5" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="805-810" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e6" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e2" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p0" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e3" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p1" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e5" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p2" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e6" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p3" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e2" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p4" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e3" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p5" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e5" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p6" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e1" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e6" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p7" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e2" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e4" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p8" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e3" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e4" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p9" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e4" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e5" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p10" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e4" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.e6" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c1.p11" relation="true"/>
  </chunk>
  <chunk id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2" text="Results: Our patient was diagnosed with SCID (T-B + NK+ phenotype). At 9 months of age, he received a T cell receptor(TCR)α/β-cell depleted graft from his haploidentical mother, following a reduced intensity conditioning regimen with no additional GvHD prophylaxis. Engraftment was rapid with complete donor chimerism and no signs of GvHD. However, at 12 weeks post HSCT, the patient was still T-cell lymphopenic with clinical symptoms of multiple severe viral infections. Consequently, therapeutic DLIs were initiated for enhanced anti-viral immunity. The patient was treated with CD45RA+ depleted haploidentical maternal donor lymphocytes enriched from unmobilized whole blood, and a total T-cell dose of no more than 25 x10 3 CD3+ cells/kg with &gt;99.9 % purity of CD3 + CD45RO+ memory T-cells was transferred. Following the DLI, a prompt increase in CD3 + CD4+ and CD3 + CD8+ counts was observed with a subsequent clearance of viral infections. No acute or chronic GvHD was observed.">
    <entity charOffset="40-44" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e0" ontology_id="DOID_627" text="SCID" type="disease"/>
    <entity charOffset="302-307" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e1" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="302-307" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e2" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <entity charOffset="623-628" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e3" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="623-628" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e4" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e1" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.p0" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e2" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.p1" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e3" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.p2" relation="true"/>
    <pair e1="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e0" e2="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.e4" id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c2.p3" relation="true"/>
  </chunk>
  <chunk id="968d0b07b0b65a15cedfd2357e3ba9649742836e.c3" text="Conclusions: Automated depletion of CD45RA+ naïve T-cells from unmobilized whole blood is a simple and rapid strategy to provide unmanipulated DLIs, with a potentially broad repertoire of pathogen specific memory T-cells. In the haploidentical setting, CD45RA+ depleted DLIs can be safely administered at low T-cell doses for efficient enhancement of viral immunity and limited risk of GvHD. We demonstrate the successful use of this approach following TCR-α/β-cell depleted HSCT for the treatment of SCID."/>
</document>
